Why BGPT?
logo

Review Papers Claim by Claim

Check each claim against its experiments, reported results, scope, and stated limitations.Know what the science actually supports before you trust the answer.

Press Enter ↡ to start review


     Quick Answer



    Mas-Coma's 2005 review establishes human fascioliasis as an emerging/re-emerging disease with the widest latitudinal-altitudinal range of any vector-borne parasitic disease, decoupling human from animal disease burden, and defining region-specific epidemiological patterns (e.g., Andean altiplanic, Caribbean insular, Afro-Mediterranean, Caspian) that demand locally tailored control; its main weaknesses are reliance on underreported, methodologically heterogeneous case data and self-citation-heavy synthesis .


     Long Answer



    Core Contribution and Evidence

    This narrative review by S. Mas-Coma (Universidad de Valencia), funded by WHO, EU, and Spanish national programs, synthesizes WHO-initiative research arguing that human fascioliasisβ€”long a secondary zoonosisβ€”became an important human parasitic disease by the mid-2000s, with estimates of 2.4 to 17 million infected people and human cases reported from 51 countries . The highest documented burden was the Northern Bolivian Altiplano, where coprological prevalence reached 72% (serological up to 100%), with intensities exceeding 5,000 epg in children; adults also showed >40% prevalence .

    The most intellectually valuable claim is that human and animal fascioliasis correlate only at a basic level: high animal burden in Uruguay, Argentina, Chile, northern Europe and Australia coexists with few human cases, while Bolivia, Peru, Egypt and Iran show hyperendemics despite lesser veterinary importanceβ€”attributed to dietary habits, hygiene, and water-contact behaviors .

    Epidemiological Patterns and Modern Validation

    The paper proposes four transmission patterns (Andean altiplanic/valley, Caribbean insular, Afro-Mediterranean lowland, Caspian epidemic) and stresses that known patterns may not fit unstudied areasβ€”control must follow local eco-epidemiology . Subsequent work supports its core framework: 2025 multi-country data (n=2,575) confirm Fasciola infection clusters with multiparasitism (95.1% of infected subjects had coinfections) and OR ~7.5 per additional helminth species, extending the ecological framing into multiparasitism . Field evaluation of MM3-COPRO ELISA in Huacullani (Bolivia) and Cajamarca (Peru)β€”areas named in the reviewβ€”achieved ~94.7% sensitivity, addressing the diagnostic heterogeneity the review flagged .

    Critical Weaknesses and Blindspots

    • Citation base and self-citation: 87 references, many from the author's own group and grey literature (unpublished reports, theses, local journals), limiting independent verification.
    • Underreporting acknowledged but unquantified: the paper notes fascioliasis is non-notifiable and largely underdiagnosed, so the 7,071 case count is a floor, not an estimateβ€”downstream citations treating it as burden data inherit this weakness .
    • Methodological heterogeneity: mixing coprological, serological, and clinical diagnoses across surveys without standardized case definitions inflates apparent prevalence ranges.
    • Geographic asymmetry of evidence: depth in the Bolivian Altiplano versus sparse, outbreak-driven data for Asia and Africa.

    Confidence: moderateβ€”the review's regional synthesis is well-sourced and later work confirms its structure, but the underlying prevalence data rest on heterogeneous, largely unstandardized surveys. Falsification would require standardized multi-country prevalence surveys showing substantially different burdens or transmission patterns than those proposed.



    Feedback:    

    Updated: September 23, 2026



     BGPT Paper Review



    Study Novelty

    70%

    Consolidated then-new WHO initiative findings (emergence, decoupling of human/animal disease, altitudinal range extremes, named transmission patterns) into the first systematic epidemiological classification of human fascioliasis endemicity.



    Scientific Quality

    80%

    Expert, extensively referenced synthesis with transparent acknowledgment of reporting biases, but narrative (no systematic search), heavy self-citation, mixed diagnostic methods, and no quantitative meta-analysis; GROBID extraction shows minor text corruption.



    Study Generality

    80%

    Explains patterns mechanistically via snail-vector ecology (Galba/Fossaria vs Radix), altitude adaptation, and behavioral risk factors, but depth is narrative rather than quantitative/model-based.



    Study Usefulness

    80%

    Directly informs control-strategy design via eco-epidemiological baselining and served as a foundational reference for subsequent work on coinfection, diagnostics, and country-level burden.



    Study Reproducibility

    50%

    A narrative review is not reproducible in an experimental sense; many underlying data come from unpublished reports, theses, and local literature that cannot be re-accessed.



    Explanatory Depth

    70%

    🎁 Authors: Collect 250 Free Science Tokens (β‰ˆ $25.0 USD)

    Claim My Author Tokens

    Use for 62 days of free BGPT access (4 tokens = 1 day) or trade/sell (β‰ˆ $25.0 USD)

     Top Data Sources ExportMCP



     Analysis Wizard



    Compiling and visualizing reported human fascioliasis case counts by continent and regional prevalence data from the 2005 review and 2025 coinfection study.



     Hypothesis Graveyard



    Hypothesis that human fascioliasis burden mirrors livestock fascioliasis burden: falsified by the geographic decoupling data in this review (high human burden in Bolivia/Peru/Egypt vs high animal burden elsewhere).

     Science Art


    Paper Review: Epidemiology of fascioliasis in human endemic areas Science Art

     Science Movie



    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT